2025-10-11 - Analysis Report
Okay, here's a comprehensive analysis of UnitedHealth Group Inc. (UNH) based on the provided data, presented in a format suitable for a report.

**Report: UnitedHealth Group Inc. (UNH) Analysis**

**1. Performance Overview**

*   **Ticker:** UNH
*   **Company Description:** UnitedHealth Group Inc. is a diversified health care company providing a wide range of products and services.
*   **Cumulative Return:** -16.82%
*   **S&P 500 (VOO) Cumulative Return:** 99.08%
*   **Absolute Divergence:** -113.3% (UNH underperforming VOO)
*   **Relative Divergence:** 10.4% (UNH is near the bottom of its historical divergence range relative to VOO).

**Analysis:** UNH has significantly underperformed the S&P 500 recently. The large negative divergence suggests a substantial deviation from the market benchmark. The relative divergence of 10.4% indicates that UNH's underperformance is near its worst historical levels compared to the S&P 500.

**Alpha and Beta Analysis Table**

| Year       | CAGR    | MDD    | Alpha   | Beta | Cap(B) |
| :----------- | :------ | :------ | :------ | :--- | :------ |
| 2015-2017  | 58.0%   | 66.4%   | 30.0%   | 0.1  | 199.6   |
| 2016-2018  | 41.0%   | 70.4%   | 26.0%   | 0.1  | 225.5   |
| 2017-2019  | 36.0%   | 73.8%   | 14.0%   | 0.2  | 266.1   |
| 2018-2020  | -43.0%  | 81.2%   | -67.0%  | 0.5  | 317.5   |
| 2019-2021  | 16.0%   | 81.2%   | -30.0%  | 1.5  | 454.6   |
| 2020-2022  | -1.0%   | 81.2%   | 0.0%    | 1.5  | 480.0   |
| 2021-2023  | 24.0%   | 80.8%   | 23.0%   | 0.4  | 476.6   |
| 2022-2024  | -27.0%  | 78.8%   | -47.0%  | 0.3  | 458.0   |
| 2023-2025  | -59.0%  | 78.8%   | -123.0% | 1.3  | 322.6   |

**Analysis:** The table reveals some concerning trends:

*   **Declining CAGR:** The Compound Annual Growth Rate (CAGR) has generally decreased over the more recent periods, with negative CAGR values in the last few years.
*   **High MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant potential losses from peak to trough.
*   **Negative Alpha:**  Recent Alpha values are negative, showing UNH has underperformed its benchmark on a risk-adjusted basis. The alpha has decreased significantly in recent years, indicating worsening performance relative to its benchmark.
*   **Beta Fluctuations:** The Beta values vary, indicating changing sensitivity to market movements. Note the increase in Beta during 2019-2022, suggesting higher correlation with the market during these periods.
*   **Decreasing Market Cap:** Market Capitalization has decreased recently.

**2. Recent Price Action**

*   **Current Price:** 356.29
*   **Last Market Close:** Price: 355.95, Previous Close: 367.69, Change: -3.19
*   **5-day Moving Average:** 361.77
*   **20-day Moving Average:** 349.40
*   **60-day Moving Average:** 308.69

**Analysis:** The current price is below the 5-day moving average, indicating a short-term downtrend. It's above the 20-day and 60-day moving averages, but the fact that the 5-day is *above* the 20-day implies some recent upward momentum. The recent close of 355.95 and negative change of -3.19 indicates a small downward pressure.

**3. Technical Indicators & Outlook**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 64.67 (Approaching Overbought)
*   **PPO:** -0.15 (Slightly Bearish Momentum)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (2 shares - Very Safe - MRI:0.90)
*   **20-day Relative Divergence Change:** 2.1% (Short-term Increase)
*   **Expected Return:** -120.6% (Long-term Underperformance vs. S&P 500)

**Analysis:**

*   **MRI & Hybrid Signal:** Despite the negative performance, the MRI suggests it's still within the "High Investment Recommended" range, which is contradicted by Expected Return.
*   **RSI:** The RSI is approaching overbought territory, suggesting a potential pullback.
*   **PPO:** The negative PPO suggests slight bearish momentum.
*   **Divergence Change:** The recent increase in relative divergence could indicate a short-term improvement, but the overall divergence is still very negative.
*   **Expected Return:**  The extremely negative expected return is concerning, indicating significant potential underperformance compared to the S&P 500 over a 2+ year investment horizon.

**4. News & Analyst Sentiment**

*   **Recent News:** Positive news regarding sector updates and quality ratings for UnitedHealth. A piece discusses Optum Rx and patient experience. Mizuho increased its price target on UnitedHealth Group to $430 From $300, Maintains Outperform Rating.
*   **Analyst Consensus:**
    *   Key: Buy
    *   Mean Rating: 1.96 (Buy)
    *   Opinions: 24
    *   Target Price (avg/high/low): 362.42 / 626.00 / 198.00

**Analysis:** Recent news is mixed, but the Mizuho price target increase is a positive catalyst.  Analyst sentiment is generally positive, with a "Buy" consensus and a target price slightly above the current price. However, the wide range in target prices (198.00 - 626.00) indicates some uncertainty among analysts.

**5. Earnings Analysis**

| 날짜         | EPS  | 매출         |
| :----------- | :--- | :----------- |
| 2025-08-11 | 3.76 | 111.62 B$ |
| 2025-05-07 | 6.9  | 109.58 B$ |
| 2024-11-04 | 6.56 | 100.82 B$ |
| 2024-08-09 | 4.58 | 98.86 B$ |
| 2025-08-11 | 4.58 | 98.86 B$ |

**Analysis:** Revenue is generally increasing over the reported quarters. EPS has been volatile. This inconsistency could contribute to investor uncertainty.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| :------------- | :---------- | :-------------- |
| 2025-06-30 | $111.62B | 17.93%        |
| 2025-03-31 | $109.58B | 21.70%        |
| 2024-12-31 | $100.81B | 21.14%        |
| 2024-09-30 | $100.82B | 22.84%        |
| 2024-06-30 | $98.86B  | 22.31%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE    |
| :------------- | :---------- | :----- |
| 2025-06-30 | $94.72B | 3.60% |
| 2025-03-31 | $95.04B | 6.62% |
| 2024-12-31 | $92.66B | 5.98% |
| 2024-09-30 | $94.53B | 6.41% |
| 2024-06-30 | $89.36B | 4.72% |

**Analysis:** Revenue shows growth over the past year. However, profit margins have decreased in the most recent quarter. Equity has increased overall, but ROE has declined significantly in the latest quarter, potentially signaling decreased efficiency in generating profits from equity.

**7. Overall Assessment**

UNH is currently facing significant challenges.

*   **Negative Performance:**  The stock has substantially underperformed the S&P 500, with a very negative divergence.
*   **Technical Concerns:**  Although the MRI is high, other technical indicators (PPO) and recent price action suggest caution. The RSI is approaching overbought levels, which could signal a pullback.
*   **Financial Concerns:** The decreasing profit margins and ROE in the most recent quarter are concerning.
*   **Positive Signals:** Recent news headlines are positive, especially the analyst price target increase. Analysts generally maintain a "Buy" rating.

**Conclusion:**

The data presents a mixed picture. While analyst sentiment and some recent news are positive, the significant underperformance relative to the S&P 500, decreasing profit margins, and declining ROE should raise caution. Given the high MRI, high MDD and Hybrid Signal, further research and monitoring of UNH's performance are warranted before making any investment decisions. The extremely negative expected return raises a serious red flag.
